<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estimated average five-year and lifetime breast-cancer risks for women with moderate-penetrance mutations in selected genes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estimated average five-year and lifetime breast-cancer risks for women with moderate-penetrance mutations in selected genes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Estimated average five-year and lifetime breast-cancer risks for women with moderate-penetrance mutations in selected genes</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="10" width="9%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Age<br/> (years)</td> <td class="subtitle1" colspan="2">Population</td> <td class="subtitle1" colspan="2"><em>ATM</em>/<em>NBN</em><br/> (RR 2.7 to 2.8)*</td> <td class="subtitle1" colspan="2"><em>CHEK2</em>(1100delC)<br/> (RR 3.0)<sup>¶</sup></td> <td class="subtitle1" colspan="2"><em>CHEK2</em>(I157T)<br/> (RR 1.58)</td> <td class="subtitle1" colspan="2"><em>PALB2</em><sup>[1]</sup></td> </tr> <tr> <td class="subtitle2">5-year (%)</td> <td class="subtitle2">Cumulative (%)</td> <td class="subtitle2">5-year (%)</td> <td class="subtitle2">Cumulative (%)</td> <td class="subtitle2">5-year (%)</td> <td class="subtitle2">Cumulative (%)</td> <td class="subtitle2">5-year (%)</td> <td class="subtitle2">Cumulative (%)</td> <td class="subtitle2">5-year (%)</td> <td class="subtitle2">Cumulative (%)</td> </tr> <tr> <td class="centered">25 to 29</td> <td class="centered">0.04</td> <td class="centered">0.1</td> <td class="centered">0.12</td> <td class="centered">0.1</td> <td class="centered">0.13</td> <td class="centered">0.2</td> <td class="centered">0.07</td> <td class="centered">0.1</td> <td class="centered">0.35</td> <td class="centered">0.4</td> </tr> <tr> <td class="centered">30 to 34</td> <td class="centered">0.14</td> <td class="centered">0.2</td> <td class="centered">0.38</td> <td class="centered">0.5</td> <td class="centered">0.41</td> <td class="centered">0.6</td> <td class="centered">0.21</td> <td class="centered">0.3</td> <td class="centered">1.05<sup>Δ</sup></td> <td class="centered">2.0</td> </tr> <tr> <td class="centered">35 to 39</td> <td class="centered">0.30</td> <td class="centered">0.5</td> <td class="centered">0.84</td> <td class="centered">1.4</td> <td class="centered">0.90</td> <td class="centered">1.5</td> <td class="centered">0.48</td> <td class="centered">0.8</td> <td class="centered">2.50<sup>◊</sup></td> <td class="centered">4.0</td> </tr> <tr> <td class="centered">40 to 44</td> <td class="centered">0.61</td> <td class="centered">1.1</td> <td class="centered">1.70<sup>Δ</sup></td> <td class="centered">3.0</td> <td class="centered">1.83<sup>Δ</sup></td> <td class="centered">3.2</td> <td class="centered">0.96<sup>Δ</sup></td> <td class="centered">1.7</td> <td class="centered">4.25<sup>◊</sup></td> <td class="centered">8.0</td> </tr> <tr> <td class="centered">45 to 49</td> <td class="centered">0.94<sup>Δ</sup></td> <td class="centered">2.0</td> <td class="centered">2.64<sup>◊</sup></td> <td class="centered">5.6</td> <td class="centered">2.83<sup>◊</sup></td> <td class="centered">5.9</td> <td class="centered">1.49<sup>Δ</sup></td> <td class="centered">3.2</td> <td class="centered">6.35<sup>◊</sup></td> <td class="centered">14.0</td> </tr> <tr> <td class="centered">50 to 54</td> <td class="centered">1.12<sup>Δ</sup></td> <td class="centered">3.1</td> <td class="centered">3.14<sup>◊</sup></td> <td class="centered">8.5</td> <td class="centered">3.36<sup>◊</sup></td> <td class="centered">9.1</td> <td class="centered">1.77<sup>Δ</sup></td> <td class="centered">4.9</td> <td class="centered">8.00<sup>◊</sup></td> <td class="centered">20.0</td> </tr> <tr> <td class="centered">55 to 59</td> <td class="centered">1.33<sup>Δ</sup></td> <td class="centered">4.4</td> <td class="centered">3.71<sup>◊</sup></td> <td class="centered">11.8</td> <td class="centered">3.98<sup>◊</sup></td> <td class="centered">12.6</td> <td class="centered">2.09<sup>Δ</sup></td> <td class="centered">6.8</td> <td class="centered">7.25<sup>◊</sup></td> <td class="centered">26.0</td> </tr> <tr> <td class="centered">60 to 64</td> <td class="centered">1.72<sup>Δ</sup></td> <td class="centered">6.0</td> <td class="centered">4.81<sup>◊</sup></td> <td class="centered">16.0</td> <td class="centered">5.15<sup>◊</sup></td> <td class="centered">17.0</td> <td class="centered">2.71<sup>◊</sup></td> <td class="centered">9.3</td> <td class="centered">7.35<sup>◊</sup></td> <td class="centered">31.0</td> </tr> <tr> <td class="centered">65 to 69</td> <td class="centered">2.11<sup>Δ</sup></td> <td class="centered">8.0</td> <td class="centered">5.92<sup>◊</sup></td> <td class="centered">20.8</td> <td class="centered">6.34<sup>◊</sup></td> <td class="centered">22.1</td> <td class="centered">3.34<sup>◊</sup></td> <td class="centered">12.3</td> <td class="centered">5.95<sup>◊</sup></td> <td class="centered">35.0</td> </tr> <tr class="divider_bottom"> <td class="centered">70 to 75</td> <td class="centered">2.20<sup>◊</sup></td> <td class="centered">10.0</td> <td class="centered">6.17<sup>◊</sup></td> <td class="centered">25.5</td> <td class="centered">6.61<sup>◊</sup></td> <td class="centered">27.1</td> <td class="centered">3.48<sup>◊</sup></td> <td class="centered">15.3</td> <td class="centered">6.70<sup>◊</sup></td> <td class="centered">40.0</td> </tr> <tr class="divider_top"> <td class="centered"><strong>CLTR (80)</strong></td> <td class="centered"><strong>NA</strong></td> <td class="centered"><strong>12.0</strong></td> <td class="centered"><strong>NA</strong></td> <td class="centered"><strong>30.0</strong></td> <td class="centered"><strong>NA</strong></td> <td class="centered"><strong>31.8</strong></td> <td class="centered"><strong>NA</strong></td> <td class="centered"><strong>18.3</strong></td> <td class="centered"><strong>NA</strong></td> <td class="centered"><strong>44.0</strong></td> </tr> </tbody></table></div><div class="graphic_lgnd">These data represent the estimated cumulative five-year incidence of breast cancer associated with moderate-penetrance mutations with established clinical validity (based on the method of Song et al<sup>[2]</sup>).</div><div class="graphic_footnotes">RR: relative risk; CLTR: cumulative lifetime risk; NA: not applicable.<br/>* <em>ATM</em> CLTR (80 years) estimated to be 27.1% with an RR of 5.0 up to age 50 years and then 2.0 thereafter (based on data from Thompson et al<sup>[3]</sup>). Data for <em>NBN</em> derived from study of a single truncating mutation.<br/>¶ <em>CHEK2</em> truncating mutation CLTR (80 years) estimated to be 23.4% if RR declines with age (according to the <em>CHEK2</em> Breast Cancer Case-Control Consortium<sup>[4]</sup>).<br/>Δ Indicates the age ranges at which five-year risk approaches or exceeds 1% (the approximate population risk of breast cancer among United States women aged 45 years).<br/><font class="lozenge">◊</font> Indicates the age ranges at which the five-year risk of breast cancer exceeds 2.2% (the highest risk estimated for United States women in the general population, specifically, those aged between 70 to 79 years).</div><div class="graphic_reference">References: 

<ol>
<li>Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371:497.</li>
<li>Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 2015; 33:2901.</li>
<li>Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97:813.</li>
<li>CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 2004; 74:1175.</li></ol>Reprinted by permission from Nature: Nature Reviews Clinical Oncology. Tung N, Domchek SM, Stadler Z, et al. Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol 2016; 13:581. Copyright © 2016. <a href="http://www.nature.com/nrclinonc/" target="_blank">http://www.nature.com/nrclinonc/</a>.</div><div id="graphicVersion">Graphic 118684 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
